Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K No X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number : 000-50679 CORCEPT THERAPEUTICS INCORPORATED ( Exact Name of Corporation as Specified in Its Charter ) Delaware ( State or other jurisdiction of incorporation or organization ) or Securities registered pursuant to Section 12 ( b ) of the Act : 149 Commonwealth Drive Menlo Park , CA 94025 ( Address of principal executive offices ) ( zip code ) Title of each class Common Stock , $ 0.001 par value Securities registered pursuant to Section 12 ( g ) of the Act : ( 650 ) 327-3270 ( Registrant's telephone number , including area code ) Trading Symbol ( s ) ( I.R.S. Employer Identification No. ) CORT 77-0487658 Name of each exchange on which registered The Nasdaq Stock Market None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Acts . Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes Indicate by check mark whether the registrant : ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) ; and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes > No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes > No